Seed Media Group

Search this blog

Profile

me%20and%20pep.jpg Shelley Batts is a Neuroscience PhD candidate at the University of Michigan. She studies hair cell regeneration in the cochlea, and is just embarking on that quixotic quest called 'thesis.' She lies awake at night pondering how science intersects with politics, culture, policy, money, medicine, and religion in an attempt to be more than just a niche scientist sitting in the oh-so-lovely ivory tower. Follow me and my parrot on the quest to get funded, get a PhD, and stay sane.
for%20blog%20cropped.JPG

Those who dwell, as scientists or laymen, among the beauties and mysteries of the earth, are never alone or weary of life. ~Rachel Carson

Subscribe via Email

Stay abreast of your favorite bloggers' latest and greatest via e-mail, via a daily digest.

Sign me up!

Recent Posts

Recent Comments

Archives

Blogroll

Highlights from Retrospectacle

Cochlear Hair Cell Regeneration

Interview With Dr. Irene Pepperberg

My Travels

Chemistry of Red Bull

On Religion and Taking the 'Red Pill'

Fibonacci Poems

Neuroscience of Cocaine Addiction

Basic Concepts: Hearing

Basic Concepts: Prions

Parrots Have Object Permanance

Video Game Addiction

Nicotine Makes You Sober

Buzz on Honeybee Cognition

Help Out A Grad Student (Me!)

My Amazon.com Wish List

Serotonin Jewelry

Alex Foundation Store

Technorati

Be My Friend on

MySpace

Commenter Policy

I love constructive comments! However, I reserve the right to delete comments that abuse this forum. Voicing your opinions is great, just be respectful. :D

Other Information

blogging_winner_2nd.jpg Openlab 2007 intel.jpg Badge.jpg thinking-blogger.jpg bloggeroftheday1.jpg bloggers%20rights.gif
I am a hard bloggin' scientist. Read the Manifesto.

liberty_waits_badge.bmp B-List Blogger
synapse.jpg

th_elogo1.jpg


My blog is worth $164,845.68.
How much is your blog worth?

Joost™

« Happy Birthday to A Very Old Squid | Main | Twisted.....Pedophile Rates Obama's Kids »

Genetic Hearing Loss Potentially Reversible

Category: Inner Ear Biology
Posted on: March 9, 2007 1:07 PM, by Shelley Batts

As I've mentioned before, my research and my lab focuses on the delivery of genes to the inner ear to repair or reverse deafness. One potential method for getting these genes into surviving cells is to insert them into a modified virus which infects the healthy inner ear cells. Following infection, the cells produce the protein of interest instead of more virus. However, this method's strength is in proof of concept rather than a direct therapy.

However, a group at Emory has devised yet another way to treat genetic deafness: compensating for a missing protein. A common cause of genetic deafness in people is the lack of the protein connexin26, caused by a mutation.

"There are millions of deaf people affected by mutations in this one gene, connexin26," Dr Lin says. "Congenital hearing loss is one of the most common human genetic birth defects, and that is why in almost all the states universal newborn hearing screening is mandated by law [including Georgia]."

In people without congenital hearing loss, connexin26 and connexin30 work together to form the cochlea's hybrid junction gaps, which facilitate intercellular communication. But when one of the proteins is missing, the hybrid junction gaps fail to work, and the cochlea's hair cells die off, leaving the body incapable of translating sounds into nerve impulses.

The group added extra connexin26 to mice that were deficient in connexin30, and found that this protein can compensate for the other.

With the additional connexin26, hearing sensitivity was restored and the expected hair cell death never occurred. Those positive findings led Dr. Lin to conclude, "The problem is simply caused by not having enough protein remaining in the ear of these mutant mice to assemble gap junctions."

Now they are running experiments to test whether connexin-related deafness can be reversed in a mouse model, or if increasing connexin30 may help when connexin26 is deficient.

Hap tip Bob Abu and Andy for the story.

TrackBacks

TrackBack URL for this entry:

Comments

...."Now they are running experiments to test whether connexin-related deafness can be reversed in a mouse model, or if increasing connexin30 may help when connexin26 is deficient."

Would experiments like these be classified as phase I, II, III, and IV--like other drugs in the pharmaceutical pipeline--as require by the FDA?

Thanks,

Mike

Posted by: mike | March 10, 2007 7:26 PM

Hi dear friend... :-)

Happy to see somebody having some interest about Cx26 and Cx30 in the cochlea.. I characterized Cx26 and Cx30 deficient mice some years ago.. and now I work on usher proteins, pearhaps u will see soon my new paper on Vlgr1 (to be published next month in j neuroscience.. :-))... Your paper on transdiferentiation was very interesting. Good luck for the end of your PhD..
...and, if you come in Paris, please come to visit our lab :-))

Have a nice day

Vincent

Posted by: Vincent | March 13, 2007 11:04 AM

Mike, as far as I know this is preliminary data and not in the FDA pipeline at all yet.

Vincent, thanks for stopping by and for the kind words. I'll be sure to check out your paper, and your lab if I'm ever in Paris! :)

Posted by: Shelley Batts | March 13, 2007 11:09 AM

Post a Comment

(Email is required for authentication purposes only. Comments are moderated for spam, your comment may not appear immediately. Thanks for waiting.)





Having problems commenting?

Search All Blogs

Blogs in the Network

Top Five: Most Active